A detailed history of Versor Investments LP transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Versor Investments LP holds 47,000 shares of CTKB stock, worth $201,160. This represents 0.05% of its overall portfolio holdings.

Number of Shares
47,000
Holding current value
$201,160
% of portfolio
0.05%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 05, 2025

BUY
$4.7 - $7.4 $220,900 - $347,800
47,000 New
47,000 $305,000
Q2 2024

Aug 01, 2024

SELL
$5.3 - $6.91 $129,850 - $169,295
-24,500 Reduced 52.24%
22,400 $124,000
Q1 2024

May 13, 2024

BUY
$6.29 - $9.15 $295,001 - $429,135
46,900 New
46,900 $314,000
Q3 2023

Nov 06, 2023

BUY
$5.52 - $9.5 $187,128 - $322,050
33,900 New
33,900 $187,000
Q1 2023

May 05, 2023

SELL
$8.44 - $13.47 $44,732 - $71,391
-5,300 Reduced 30.46%
12,100 $111,000
Q4 2022

Jan 30, 2023

BUY
$9.71 - $15.86 $168,954 - $275,964
17,400 New
17,400 $177,000

Others Institutions Holding CTKB

About Cytek Biosciences, Inc.


  • Ticker CTKB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 134,627,008
  • Market Cap $576M
  • Description
  • Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...
More about CTKB
Track This Portfolio

Track Versor Investments LP Portfolio

Follow Versor Investments LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versor Investments LP, based on Form 13F filings with the SEC.

News

Stay updated on Versor Investments LP with notifications on news.